JAZ mediates G1 cell cycle arrest by interacting with and inhibiting E2F1

Cell Cycle

Volumn 10, Issue 14, 2011, Pages 2390-2399

  Yang, Mingli ^a   Wu, Song ^a,b   Jia, Jinghua ^a   May, W Stratford ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

E2F1; JAZ; P53

Indexed keywords

GROWTH FACTOR; JUST ANOTHER ZINC FINGER PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; CYCLIN A; DNA; DNA BINDING PROTEIN; PROTEIN P53; RNA BINDING PROTEIN; ZFP346 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL INTERACTION; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; DIMERIZATION; DNA BINDING; EMBRYO; GROWTH DISORDER; GROWTH INHIBITION; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSACTIVATION; TRANSCRIPTION INITIATION; ANIMAL; CELL LINE; DRUG ANTAGONISM; GENETICS; METABOLISM; RNA INTERFERENCE;

ANIMALS; CELL LINE; CYCLIN A; DNA; DNA-BINDING PROTEINS; E2F1 TRANSCRIPTION FACTOR; G1 PHASE; MICE; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; ZINC FINGERS;

EID: 79960464138     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.14.16587     Document Type: Article

References (57)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10; DOI: 10.1038/35042675; PMID: 11099028.
2. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749-58; DOI: 10.1038/nrc2723; PMID: 19776744.
3. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137:413-31; DOI: 10.1016/j.cell.2009.04.037; PMID: 19410540.
4. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604; DOI: 10.1038/nrc864; PMID: 12154352.
5. Yang M, May WS, Ito T. JAZ requires the double-stranded RNA-binding zinc finger motifs for nuclear localization. J Biol Chem 1999; 274:27399-406; DOI: 10.1074/jbc.274.39.27399; PMID: 10488071.
6. Finerty PJ, Bass BL. A xenopus zinc finger protein that specifically binds dsRNA and RNA-DNA hybrids. J Mol Biol 1997; 271:195-208; DOI: 10.1006/jmbi.1997.1177; PMID: 9268652.
7. Méndez-Vidal C, Wilhelm MT, Hellborg F, Qian W, Wiman KG. The p53-induced mouse zinc finger protein wig-1 binds double-stranded RNA with high affinity. Nucleic Acids Res 2002; 30:1991-6; DOI: 10.1093/nar/30.9.1991; PMID: 11972337.
8. Chen T, Brownawell AM, Macara IG. Nucleocytoplasmic shuttling of JAZ, a new cargo protein for exportin-5. Mol Cell Biol 2004; 24:6608-19; DOI: 10.1128/MCB.24.15.6608-19.2004; PMID: 15254228.
9. May WS. Control of apoptosis by cytokines. Adv Pharmacol 1997; 41:219-46; DOI: 10.1016/S1054-3589(08)61060-1; PMID: 9204147.
10. Johnson DE. Regulation of survival pathways by IL-3 and induction of apoptosis following IL-3 withdrawal. Front Biosci 1998; 3:313-24; PMID: 9488657.
11. Ito T, Jagus R, May WS. Interleukin 3 stimulates protein synthesis by regulating double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci USA 1994; 91:7455-9; DOI: 10.1073/pnas.91.16.7455; PMID: 7519779.
12. Gottlieb E, Oren M. p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J 1998; 17:3587-96; DOI: 10.1093/emboj/17.13.3587; PMID: 9649429.
13. Blandino G, Scardigli R, Rizzo MG, Crescenzi M, Soddu S, Sacchi A. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene 1995; 10:731-7; PMID: 7862450.
14. 1 cell cycle arrest and apoptosis by positively regulating p53 transcriptional activity. Blood 2006; 108:4136-45; DOI: 10.1182/blood-2006-06-029645; PMID: 16931621.
15. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-95; PMID: 10919634.
16. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12:2245-62; DOI: 10.1101/gad.12.15.2245; PMID: 9694791.
17. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10:699-703; DOI: 10.1093/hmg/10.7.699; PMID: 11257102.
18. Tsantoulis PK, Gorgoulis VG. Involvement of E2F transcription factor family in cancer. Eur J Cancer 2005; 41:2403-14; DOI: 10.1016/j.ejca.2005.08. 005; PMID: 16213134.
19. Helin K, Lees JA, Vidal M, Dyson N, Harlow E, Fattaey A. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 1992; 70:337-50; DOI: 10.1016/0092-8674(92)90107-N; PMID: 1638634.
20. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993; 365:349-52; DOI: 10.1038/365349a0; PMID: 8377827.
21. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 1993; 13:6501-8; PMID: 8413249.
22. Flemington EK, Speck SH, Kaelin WG Jr. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1993; 90:6914-8; DOI: 10.1073/pnas.90.15.6914; PMID: 8346196.
23. Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, Kaelin WG Jr. The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol 1995; 15:742-55; PMID: 7823942.
24. Singh P, Wong SH, Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 1994; 13:3329-38; PMID: 8045262.
25. Gala S, Marreiros A, Stewart GJ, Williamson P. Overexpression of E2F-1 leads to cytokine-independent proliferation and survival in the hematopoietic cell line BaF-B03. Blood 2001; 97:227-34; DOI: 10.1182/blood.V97.1.227; PMID: 11133765.
26. Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007; 67:4149-56; DOI: 10.1158/0008-5472.CAN-06-4484; PMID: 17483325.
27. Baldini E, Camerini A, Sgambato A, Prochilo T, Capodanno A, Pasqualetti F, et al. CyclinA and E2F1 overexpression correlate with reduced disease-free survival in Node-negative breast cancer patients. Anticancer Res 2006; 26:4415-21; PMID: 17201163.
28. Lao-Sirieix P, Lovat L, Fitzgerald RC. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res 2007; 13:659-65; DOI: 10.1158/1078-0432.CCR-06-1385; PMID: 17255290.
29. Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimäki A. Prognostic significance of cyclin A in gastric cancer. Int J Cancer 2006; 119:1897-901; DOI: 10.1002/ijc.21944; PMID: 16708383.
30. Holm C, Ora I, Brunhoff C, Anagnostaki L, Landberg G, Persson JL. Cyclin A1 expression and associations with disease characteristics in childhood acute lymphoblastic leukemia. Leuk Res 2006; 30:254-61; DOI: 10.1016/j.leukres.2005. 07.010; PMID: 16182364.
31. Poikonen P, Sjöström J, Amini RM, Villman K, Ahlgren J, Blomqvist C. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer 2005; 93:515-9; DOI: 10.1038/sj.bjc.6602735; PMID: 16091759.
32. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12; DOI: 10.1016/S1535-6108(02)00102-2; PMID: 12204530.
33. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9:738-48; DOI: 10.1038/nrc2718; PMID: 19776743.
34. Martin K, Trouche D, Hagemeier C, Sørensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375:691-4; DOI: 10.1038/375691a0; PMID: 7791903.
35. Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005; 24:7238-47; DOI: 10.1038/sj.onc.1208814; PMID: 16170383.
36. Eymin B, Karayan L, Séité P, Brambilla C, Brambilla E, Larsen CJ, et al. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20:1033-41; DOI: 10.1038/sj.onc.1204220; PMID: 11314038.
37. ARF regulates E2F activity. Oncogene 2002; 21:4220-30; DOI: 10.1038/sj.onc.1205524; PMID: 12082609.
38. Datta A, Nag A, Raychaudhuri P. Differential regulation of E2F1, DP1 and the E2F1/DP1 complex by ARF. Mol Cell Biol 2002; 22:8398-408; DOI: 10.1128/MCB.22.24.8398-408.2002; PMID: 12446760.
39. 1 arrest function of ARF. Mol Cell Biol 2005; 25:8024-36; DOI: 10.1128/MCB.25.18.8024- 36.2005; PMID: 16135794.
40. Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 2006; 8:1025-31; DOI: 10.1038/ncb1468; PMID: 16892051.
41. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991; 67:1169-79; DOI: 10.1016/0092-8674(91)90293-8; PMID: 1836977.
42. 1 arrest, and a C-terminal region for mitosis. EMBO J 2001; 20:2376-86; DOI: 10.1093/emboj/20.10.2376; PMID: 11350926.
43. Chibazakura T, Kamachi K, Ohara M, Tane S, Yoshikawa H, Roberts JM. Cyclin A promotes S-phase entry via interaction with the replication licensing factor Mcm7. Mol Cell Biol 2011; 31:248-55; DOI: 10.1128/MCB.00630-10; PMID: 21078875.
44. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25; DOI: 10.1016/0092-8674(93)90500-P; PMID: 8242752.
45. 1/S-regulatory genes. Mol Cell Biol 1995; 15:4215-24; PMID: 7623816.
46. Liu K, Lin FT, Ruppert JM, Lin WC. Regulation of E2F1 by BRCT domain-containing protein TopBP1. Mol Cell Biol 2003; 23:3287-304; DOI: 10.1128/MCB.23.9.3287-304.2003; PMID: 12697828.
47. Bernardi R, Liebermann DA, Hoffman B. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 2000; 19:2447-54; DOI: 10.1038/sj.onc.1203564; PMID: 10828887.
48. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci 1998; 23:291-6; DOI: 10.1016/S0968-0004(98)01236-5; PMID: 9757829.
49. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000; 10:94-9; DOI: 10.1016/S0959-437X(99)00038-6; PMID: 10679383.
50. Modestou M, Puig-Antich V, Korgaonkar C, Eapen A, Quelle DE. The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways. Cancer Res 2001; 61:3145-50; PMID: 11306500.
51. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003; 11:415-24; DOI: 10.1016/S1097-2765(03)00057-1; PMID: 12620229.
52. Cress WD, Nevins JR. A role for a bent DNA structure in E2F-mediated transcription activation. Mol Cell Biol 1996; 16:2119-27; PMID: 8628278.
53. Trouche D, Kouzarides T. E2F1 and E1A(12S) have a homologous activation domain regulated by RB and CBP. Proc Natl Acad Sci USA 1996; 93:1439-42; DOI: 10.1073/pnas.93.4.1439; PMID: 8643650.
54. Ma Y, Chen L, Wright GM, Pillai SR, Chellappan SP, Cress WD. CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner. J Biol Chem 2010; 285:9813-22; DOI: 10.1074/jbc.M109. 091496; PMID: 20106982.
55. Lam EWF, Bennett JS, Watson RJ. Cell cycle regulation of human B-myb transcription. Gene 1995; 160:277-81; DOI: 10.1016/0378-1119(95)00184-8; PMID: 7642110.
56. Pierani A, Pouponnot C, Calothy G. Transcriptional downregulation of the retina-specific QR1 gene pp60v-src and identification of a novel v-src-responsible unit. Mol Cell Biol 1993; 13:3401-14; PMID: 8388536.
57. Schmid I, Sakamoto KM. Analysis of DNA content and green fluorescent protein expression. In: Robinson JP, Darzynkiewicz Z, Dean P, Orfao A, Rabinovitch P, Stewart C, Editors, et al. Current Protocols in Cytometry. New York: John Wiley & Sons 2001; 7:1 10.